Obermatt
See Similar Stocks →

Immatics

NAQ:IMTX · NL0015285941
BiotechnologySmall

360

31
Profit price25
Owner Earnings Yield1
Dividend Yield1
Price/Sales17
Price/Book31
Return on Capital51
Cash Return on Capital48
Return on Equity51
Profit margins15
Accruals89
Owner Earnings Margin22
Sales growth21
Profit growth16
Reinvestment43
Price momentum81
Debt load70
Refinancing35
Debt Payback1
Liquidity45
Analyst ratings100
Opinion Changes50
Price Target Upside61
Market mood67
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Immatics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryGermany
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees563
Websiteimmatics.com
ISINNL0015285941
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Artificial IntelligenceGeneticsImmunologyVaccinesStem Cell TherapyOncologyBiotechnologyMedicalTherapeutics

Description

Immatics N.V. (Immatics) operates as a clinical-stage biopharmaceutical company. The company is a global enterprise specializing in precision targeting of PRAME, a target expressed in more than 50 cancers. The company’s science and robust clinical p…

Analysis

Middle-of-the-road

Immatics N.V. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
58
2026

All-time high

58

Jun 2026

All-time low

33

Mar 2026

Average rank

46

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
17
—
—
—
Price/Earnings
45
—
—
—
Price/Book
31
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
11
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Immatics with its peers
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Heidelberg Pharma
GER:HPHA
32
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →